Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2002 + Adebrelimab + Docetaxel in pretreated advanced NSCLC (driver-negative) – Phase 2
ChiCTR2400086491Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-2002, adebrelimab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate and Overall survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
SHR-2002adebrelimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086491.